BIOMARK GRANTS OPTIONS
Vancouver, British Columbia – (March 2, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has granted 2,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each […]
BIOMARK AND PHYTRONIX TECHNOLOGIES INC. ENTER INTO A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT
Vancouver, British Columbia – (February 16, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. (“Phytronix”) to advance the development of BioMark’s early lung cancer screening applications […]
Missing cancer cases a worrying pandemic trend
Elizabeth PaynePublishing date:Feb 04, 2021 Fewer Canadians have been diagnosed with cancer during the COVID-19 pandemic compared with previous years. Far from being something to celebrate, it is part of a global trend that is raising alarm bells. Across Canada, diagnoses are down by around 16 per cent overall and as much as 25 per […]
BIOMARK DIAGNOSTICS TARGETS RESPONSE TO TREATMENT APPLICATION WITH ITS LIQUID BIOPSY PLATFORM
Vancouver, British Columbia – (February 8, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer – a Pilot Study” has been published in the peer-reviewed journal Future Science OA. Rashid A. Bux, […]
World Cancer Day: A leading international awareness day
World Cancer Day every 4 February is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalysing personal, collective and government action, we’re working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equal for all – no matter who […]
Doctors fear an impending wave of cancer patients after COVID-19 delays
BY MORGAN LOWRIE, THE CANADIAN PRESS Posted Feb 4, 2021 10:24 am PST MONTREAL, Italy — While the prospectof mass vaccination has raised hopes of the COVID-19 crisis soon waning, oncologists and cancer researchers say one of its grim legacies may be a lingering increase in cancer mortality rates. The pandemic caused a “dramatic” drop in […]
Alfred Berkeley Joins BioMark’s Advisory Team
Vancouver, British Columbia – (January 11, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is glad to announce Alfred Berkeley as a new member of the BioMark’s Advisory team as he will be providing strategic and financial advice to help expand the company’s commercialization effort in the U.S. Mr. Rashid Ahmed […]
BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES
Vancouver, British Columbia – (December 7th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that it has retained Questrade, Inc. (“Questrade”) to provide market-making services in accordance with CSE guidelines. The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either […]
Richmond company looking for ‘holy grail’ in COVID-19 testing
A rapid COVID-19 saliva test could be used wherever crowds gatherMaria Rantanen / Richmond News A Richmond biomedical company is in a race to create a rapid, cheap and portable saliva test for COVID-19 to help open up the economy and give people more freedom to move. Rashid Bux — president and CEO of BioMark Diagnostics […]
BIOMARK SCIENTIFIC ADVISOR DR. DONALD MILLER TO PRESENT AT THE DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP
Vancouver, British Columbia – (September 23rd, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark’s SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion […]
